This inventor holds 1 USPTO granted patent. Top assignee: Neophore Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: David Clark - Innovator in Cancer Treatment
Introduction
David Clark is a notable inventor based in Saffron Walden, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on targeting specific proteins involved in the DNA Mismatch Repair process.
Latest Patents
David Clark holds a patent for "Inhibitors of MLH1 and/or PMS2 for cancer treatment." This invention relates to compounds of Formula (I) that specifically target the MLH1 and/or PMS2 proteins, which are crucial components of the DNA Mismatch Repair (MMR) process. This patent represents a significant advancement in the fight against cancer.
Career Highlights
Throughout his career, David has been associated with Neophore Limited, a company dedicated to developing innovative therapies for cancer treatment. His work has been instrumental in advancing the understanding of how to effectively target cancer cells.
Collaborations
David has collaborated with notable colleagues, including Jon Roffey and Martin Drysdale. These partnerships have enhanced the research and development efforts at Neophore Limited, contributing to the advancement of cancer therapies.
Conclusion
David Clark's innovative work in cancer treatment exemplifies the impact of targeted therapies in modern medicine. His contributions continue to pave the way for new treatment options for patients battling cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile